OLIPASS
OliPass Corporation is committed to revolutionize our views of life sciences and bring us great quality of life.
OLIPASS
Industry:
Biotechnology Life Science
Founded:
2006-01-01
Address:
Suwon, Ch'ungch'ong-namdo, South Korea
Country:
South Korea
Website Url:
http://www.olipass.com
Total Employee:
51+
Status:
Active
Total Funding:
20 B KRW
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Apache
Similar Organizations
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Shin Chung Founder & CEO @ Olipass
Founder & CEO
Founder
Investors List
Geon Investment
Geon Investment investment in Venture Round - Olipass
Official Site Inspections
http://www.olipass.com
- Host name: 104.21.23.103
- IP address: 104.21.23.103
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Olipass"
Olipass - Crunchbase Company Profile & Funding
OliPass is always collaborating to develop new ways to give a happy and healthy existence for everyone on the planet. OliPass Corporation is dedicated to changing people's perceptions of …See details»
OliPass
OliPass is dedicated to providing safe and feasible options for healthy aging. History. 2020’s. 2022 09 Drug development R&D collaboration with Vanda Pharmaceuticals Inc. 09 Presented …See details»
OliPass
OliPass PNA is highly permeable to skin, so it is also suitable to be developed for treating various skin diseases such as atopic dermatitis, psoriasis and the like. Also due to its excellent skin …See details»
Shin Chung님 - CEO - OliPass Corporation - LinkedIn
Nov 19, 2018 Founder & CEO, OliPass Corporation · I have been in the pharmaceutical industry and involved in drug discovery and development for more than 30 years. My professional …See details»
OliPass
OliPass PNA(OPNA) 페이지 바로가기 OliPass Peptide Nucleic Acid (OliPass PNA) is derived from PNA by rationally introducing cationic lipid moiety onto nucleobase. By covalently attaching …See details»
OliPass - VentureRadar
Since 2006, OliPass has been committed to revolutionizing the life sciences and improving the quality of life. Our research is focused on developing a new generation of therapeutics using …See details»
OliPass Corporation Overview | SignalHire Company Profile
Organization Website: olipass.com : Phone Number +82-2-6488-2239: OliPass Corporation industries ... OliPass Corporation headquarters is in 서울시, 강동구 천호대로 1077 …See details»
OLIPASS Corporation: Shareholders, Shareholding Structure
OliPass Corporation is a Korea-based company principally engaged in the research and development of bio medicine. The Company principally manufactures and sells nonopioid …See details»
올리패스 알엔에이 Real Beauty
Jan 11, 2022 company : (주)올리패스 알엔에이 ceo : 정신 business licence : [299-87-00218] e-commerce permit 제2017-용인기흥-0807호 [사업자정보확인] phone : 02-6488-2373 fax : 02 …See details»
Home | Citeline
Clinical Citeline Clinical provides comprehensive real-time R&D intelligence to the life sciences industry, featuring an unmatched data collection of global clinical trials, vetted investigators, trial …See details»
Olipass Corporation (244460) Income Statement - Investing.com AU
The Income Statement (earnings report) for Olipass Corporation. Find the company's financial performance, revenue, and more.See details»
OliPass
OliPass PNA(OPNA)는 PNA의 일부 핵산 염기에 "양이온성 지질기"를 화학적으로 도입한 "PNA 유도체"입니다. 이러한 "OPNA"는 세포투과성이 뛰어나 핵내 약물 분포가 용이하여 Exon …See details»
Vanda 和 OliPass 达成战略合作伙伴关系，共同开发反义寡核苷酸 …
欢迎关注凯莱英药闻. 2022年9月29日，Vanda Pharmaceuticals（简称“Vanda”）和OliPass公司共同宣布，二者已达成一项研发合作协议，共同开发基于OliPass专有修饰 肽核酸 的反义寡核苷 …See details»
올리패스(OliPass) 기업 및 산업 분석! : 네이버 블로그
올리패스는 2006년 11월에 설립되어 세포투과성이 우수한 올리고뉴클레오티드를 만드는 고유의 플랫폼 기술을 기반으로 rna 치료제 신약개발을 주력사업으로 영위 하고 있습니다. 회사는 현재 …See details»
OliPass Discloses Painful but Hilarious Clinical Findings from a …
SEOUL, South Korea, Nov. 13, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed uncanny clinical findings from a multi-center Phase 2a trial with …See details»
Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy
Mar 16, 2023 OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy …See details»
OliPass
However as the mechanism of action of OliPass PNA has been elucidated as exon skipping, we plan to invest our R&D to build a portfolio of pipelines focusing on clinical development. In …See details»
OLP-1002 / Olipass - LARVOL DELTA - delta.larvol.com
Olipass acquires patent for non-narcotic painkiller 'OLP-1002' [Google translation] (HIT News) - "Olipass...has acquired a Chinese patent for 'OLP-1002 (development code name)', a non …See details»
OliPass
아울러 "OliPass PNA"는 유전자 결합력이 매우 강한 특성도 보유하고 있습니다. "OliPass PNA"는 별도의 제형 없이 세포 및 동물에서 치료 효능이 얻어지기 때문에 "인공유전자 치료제"개발에 매우 …See details»
OLP-1002 (OLP-1002) - 药物靶点：Nav1.7_在研适应症：骨关节 …
OLP-1002: 一种SCN9A基因抑制剂药物，由OliPass Corp. (OliPass Corp.)公司最早进行研发，目前全球最高研发状态为临床2期，作用机制: SCN9A基因抑制剂(IX型钠通道蛋白α亚基基因抑 …See details»